

North Central Cancer Treatment Group

N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age  $\geq 70$  yrs) with Good Performance Status (PS  $< 2$ )

Revised Status Change – November 2, 2009

**NOTICE OF STATUS CHANGE**

This study was actually temporarily suspended to patient accrual effective Monday, November 2, 2009.

**Please retain this notice with the protocol.**